vs
GEN Restaurant Group, Inc.（GENK）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
GEN Restaurant Group, Inc.的季度营收约是REGENXBIO Inc.的1.6倍（$49.7M vs $30.3M），GEN Restaurant Group, Inc.净利率更高（-3.8% vs -221.3%，领先217.5%），REGENXBIO Inc.同比增速更快（43.0% vs -9.0%），GEN Restaurant Group, Inc.自由现金流更多（$-5.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -1.0%）
GEN韩式烤肉是美国的韩式烤肉自助连锁品牌，门店主要集中于美国西部地区，品牌创立于2011年，截至2024年已发展至43家门店，主打任食韩式烤肉产品，在当地拥有较高的知名度。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
GENK vs RGNX — 直观对比
营收规模更大
GENK
是对方的1.6倍
$30.3M
营收增速更快
RGNX
高出52.0%
-9.0%
净利率更高
GENK
高出217.5%
-221.3%
自由现金流更多
GENK
多$47.2M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-1.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $49.7M | $30.3M |
| 净利润 | $-1.9M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -24.5% | -190.0% |
| 净利率 | -3.8% | -221.3% |
| 营收同比 | -9.0% | 43.0% |
| 净利润同比 | -821.4% | -31.2% |
| 每股收益（稀释后） | $-0.37 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GENKRGNX
| Q4 25 | $49.7M | $30.3M | ||
| Q3 25 | $50.4M | $29.7M | ||
| Q2 25 | $55.0M | $21.4M | ||
| Q1 25 | $57.3M | $89.0M | ||
| Q4 24 | $54.7M | $21.2M | ||
| Q3 24 | $49.1M | $24.2M | ||
| Q2 24 | $53.9M | $22.3M | ||
| Q1 24 | $50.8M | $15.6M |
净利润GENKRGNX
| Q4 25 | $-1.9M | $-67.1M | ||
| Q3 25 | $-566.0K | $-61.9M | ||
| Q2 25 | $-261.0K | $-70.9M | ||
| Q1 25 | $-301.0K | $6.1M | ||
| Q4 24 | $-206.0K | $-51.2M | ||
| Q3 24 | $25.0K | $-59.6M | ||
| Q2 24 | $277.0K | $-53.0M | ||
| Q1 24 | $496.0K | $-63.3M |
毛利率GENKRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率GENKRGNX
| Q4 25 | -24.5% | -190.0% | ||
| Q3 25 | -7.4% | -176.3% | ||
| Q2 25 | -3.4% | -296.3% | ||
| Q1 25 | -3.8% | 13.6% | ||
| Q4 24 | -2.4% | -242.1% | ||
| Q3 24 | 0.2% | -256.6% | ||
| Q2 24 | 3.0% | -251.3% | ||
| Q1 24 | 0.2% | -408.8% |
净利率GENKRGNX
| Q4 25 | -3.8% | -221.3% | ||
| Q3 25 | -1.1% | -208.3% | ||
| Q2 25 | -0.5% | -331.8% | ||
| Q1 25 | -0.5% | 6.8% | ||
| Q4 24 | -0.4% | -241.3% | ||
| Q3 24 | 0.1% | -246.3% | ||
| Q2 24 | 0.5% | -237.7% | ||
| Q1 24 | 1.0% | -405.4% |
每股收益（稀释后）GENKRGNX
| Q4 25 | $-0.37 | $-1.30 | ||
| Q3 25 | $-0.11 | $-1.20 | ||
| Q2 25 | $-0.05 | $-1.38 | ||
| Q1 25 | $-0.06 | $0.12 | ||
| Q4 24 | $-0.05 | $-0.99 | ||
| Q3 24 | $0.01 | $-1.17 | ||
| Q2 24 | $0.06 | $-1.05 | ||
| Q1 24 | $0.11 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.8M | $230.1M |
| 总债务越低越好 | $13.6M | — |
| 股东权益账面价值 | $26.5M | $102.7M |
| 总资产 | $259.9M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.51× | — |
8季度趋势，按日历期对齐
现金及短期投资GENKRGNX
| Q4 25 | $2.8M | $230.1M | ||
| Q3 25 | $4.8M | $274.2M | ||
| Q2 25 | $9.6M | $323.3M | ||
| Q1 25 | $15.4M | $267.9M | ||
| Q4 24 | $23.7M | $234.7M | ||
| Q3 24 | $22.1M | $255.5M | ||
| Q2 24 | $29.2M | $290.4M | ||
| Q1 24 | $28.1M | $338.7M |
总债务GENKRGNX
| Q4 25 | $13.6M | — | ||
| Q3 25 | $10.8M | — | ||
| Q2 25 | $7.8M | — | ||
| Q1 25 | $6.5M | — | ||
| Q4 24 | $6.9M | — | ||
| Q3 24 | $7.2M | — | ||
| Q2 24 | $7.6M | — | ||
| Q1 24 | $7.7M | — |
股东权益GENKRGNX
| Q4 25 | $26.5M | $102.7M | ||
| Q3 25 | $38.1M | $161.5M | ||
| Q2 25 | $41.0M | $213.7M | ||
| Q1 25 | $42.8M | $274.2M | ||
| Q4 24 | $44.1M | $259.7M | ||
| Q3 24 | $46.5M | $301.4M | ||
| Q2 24 | $45.9M | $348.3M | ||
| Q1 24 | $40.4M | $390.7M |
总资产GENKRGNX
| Q4 25 | $259.9M | $453.0M | ||
| Q3 25 | $245.5M | $525.2M | ||
| Q2 25 | $246.3M | $581.0M | ||
| Q1 25 | $232.4M | $490.9M | ||
| Q4 24 | $240.4M | $466.0M | ||
| Q3 24 | $225.7M | $519.1M | ||
| Q2 24 | $218.8M | $569.4M | ||
| Q1 24 | $214.5M | $629.2M |
负债/权益比GENKRGNX
| Q4 25 | 0.51× | — | ||
| Q3 25 | 0.28× | — | ||
| Q2 25 | 0.19× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.16× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.17× | — | ||
| Q1 24 | 0.19× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-426.0K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-5.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | -11.3% | -174.0% |
| 资本支出强度资本支出/营收 | 10.5% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-24.3M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流GENKRGNX
| Q4 25 | $-426.0K | $-52.3M | ||
| Q3 25 | $-1.6M | $-56.0M | ||
| Q2 25 | $3.3M | $-49.3M | ||
| Q1 25 | $2.2M | $33.6M | ||
| Q4 24 | $7.3M | $-31.6M | ||
| Q3 24 | $1.4M | $-40.5M | ||
| Q2 24 | $5.6M | $-45.5M | ||
| Q1 24 | $3.5M | $-55.5M |
自由现金流GENKRGNX
| Q4 25 | $-5.6M | $-52.8M | ||
| Q3 25 | $-7.7M | $-56.5M | ||
| Q2 25 | $-6.3M | $-49.7M | ||
| Q1 25 | $-4.7M | $32.6M | ||
| Q4 24 | $165.0K | $-32.7M | ||
| Q3 24 | $-6.8M | $-40.9M | ||
| Q2 24 | $1.2M | $-46.0M | ||
| Q1 24 | $-586.0K | $-56.0M |
自由现金流率GENKRGNX
| Q4 25 | -11.3% | -174.0% | ||
| Q3 25 | -15.3% | -189.9% | ||
| Q2 25 | -11.5% | -232.8% | ||
| Q1 25 | -8.2% | 36.6% | ||
| Q4 24 | 0.3% | -154.2% | ||
| Q3 24 | -13.9% | -168.9% | ||
| Q2 24 | 2.3% | -206.2% | ||
| Q1 24 | -1.2% | -358.5% |
资本支出强度GENKRGNX
| Q4 25 | 10.5% | 1.7% | ||
| Q3 25 | 12.0% | 1.7% | ||
| Q2 25 | 17.5% | 1.8% | ||
| Q1 25 | 11.9% | 1.2% | ||
| Q4 24 | 13.1% | 5.1% | ||
| Q3 24 | 16.9% | 1.3% | ||
| Q2 24 | 8.0% | 2.1% | ||
| Q1 24 | 8.1% | 3.6% |
现金转化率GENKRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 57.96× | — | ||
| Q2 24 | 20.06× | — | ||
| Q1 24 | 7.08× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GENK
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
